Brian J Liddicoat
Overview
Explore the profile of Brian J Liddicoat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
805
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guirguis A, Liddicoat B, Dawson M
Exp Hematol
. 2020 Sep;
90:1-11.
PMID: 32961299
Whilst DNA cytosine methylation is the oldest and most well-studied epigenetic modification, basking in its glory days, it may be soon overshadowed by the new kid on the block: RNA...
2.
Liddicoat B, Dawson M
Mol Cell
. 2020 Jun;
78(6):991-993.
PMID: 32559426
Combination therapy remains the cornerstone for cancer management, and understanding how to rationally partner drugs is imperative. In this issue of Molecular Cell, Shu et al. (2020) provide a tour...
3.
Sperling A, Burgess M, Keshishian H, Gasser J, Bhatt S, Jan M, et al.
Blood
. 2019 May;
134(2):160-170.
PMID: 31043423
Pharmacologic agents that modulate ubiquitin ligase activity to induce protein degradation are a major new class of therapeutic agents, active in a number of hematologic malignancies. However, we currently have...
4.
Sievers Q, Petzold G, Bunker R, Renneville A, Slabicki M, Liddicoat B, et al.
Science
. 2018 Nov;
362(6414).
PMID: 30385546
The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys-His (C2H2) zinc finger domain...
5.
Quinn K, Kan W, Watson K, Liddicoat B, Swan N, McQuilten H, et al.
PLoS One
. 2017 Sep;
12(9):e0184732.
PMID: 28886201
TNF is a pro-inflammatory cytokine produced by both lymphoid and non-lymphoid cells. As a consequence of the widespread expression of its receptors (TNFR1 and 2), TNF plays a role in...
6.
Heraud-Farlow J, Chalk A, Linder S, Li Q, Taylor S, White J, et al.
Genome Biol
. 2017 Sep;
18(1):166.
PMID: 28874170
Background: Adenosine-to-inosine (A-to-I) editing of dsRNA by ADAR proteins is a pervasive epitranscriptome feature. Tens of thousands of A-to-I editing events are defined in the mouse, yet the functional impact...
7.
Liddicoat B, Hartner J, Piskol R, Ramaswami G, Chalk A, Kingsley P, et al.
Exp Hematol
. 2016 Jul;
44(10):947-63.
PMID: 27373493
Adenosine deaminases that act on RNA (ADARs) convert adenosine residues to inosine in double-stranded RNA. In vivo, ADAR1 is essential for the maintenance of hematopoietic stem/progenitors. Whether other hematopoietic cell...
8.
Liddicoat B, Chalk A, Walkley C
Wiley Interdiscip Rev RNA
. 2015 Dec;
7(2):157-72.
PMID: 26692549
The conversion of genomically encoded adenosine to inosine in dsRNA is termed as A-to-I RNA editing. This process is catalyzed by two of the three mammalian ADAR proteins (ADAR1 and...
9.
Liddicoat B, Piskol R, Chalk A, Ramaswami G, Higuchi M, Hartner J, et al.
Science
. 2015 Aug;
349(6252):1115-20.
PMID: 26275108
Adenosine-to-inosine (A-to-I) editing is a highly prevalent posttranscriptional modification of RNA, mediated by ADAR (adenosine deaminase acting on RNA) enzymes. In addition to RNA editing, additional functions have been proposed...